PATENT CLAIM ANALYSIS

Application Number: 16289451
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "005400"]

Abstract:
The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

Claim (Index 9):
The method of  claim 1 , wherein the peptide comprises one of the following sequences or structures: (SEQ\u2003ID\u2003NO:\u200329) Isovaleric\u2003acid-DTHFPICIFGPRSKGWVC-NH 2 ;   (SEQ\u2003ID\u2003NO:\u200338) Isovaleric\u2003acid-DTHFPCIIFGPRSKGWVCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003128) Isovaleric\u2003acid-DTHFPCIIFEPRSKGWVCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003164) Isovaleric\u2003acid-DTHFPCIIFGPRSKGWACK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003168) Isovaleric\u2003acid-DTHFPCIIFGPRSKGWVCKK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u200357) Isovaleric\u2003acid-DTHFPCIIFVCHRPKGCYRRVCR-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003172) Isovaleric\u2003acid-DTHFPCI(K(PEG8))FGPRSKGWVCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003173) Isovaleric\u2003acid-DTHFPCIKF(K(PEG8))PRSKGWVCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003199) Isovaleric\u2003acid-DTHFPICIFGPRS(K(PEG8))GWVCNH 2 ;   (SEQ\u2003ID\u2003NO:\u2003200) Isovaleric\u2003acid-DTHFPICIFGPRS(K(PEG4))GWVCNH 2 ;   (SEQ\u2003ID\u2003NO:\u2003201) Isovaleric\u2003acid-DTHFPCIIFGPRSRGWVC(K(PEG8))-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003202) Isovaleric\u2003acid-DTHFPCIIFGPRSRGWVC(K(PEG4))-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003203) Isovaleric\u2003acid-DTHFPCIIFGPRSRGWVC(K(PEG2))-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003183) Isovaleric\u2003acid-DTHFPCI(K(Palm))FGPRSKGWVCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003217) Isovaleric\u2003acid-DTHFPCIKF)K(Palm))PRSKGWVCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003219) Isovaleric\u2003acid-DTHFPCIKFGP(K(Palm))SKGWVCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003220) Isovaleric\u2003acid-DTHFPCIKFGPRS(K(Palm))GWVCK-NH2;   (SEQ\u2003ID\u2003NO:\u2003221) Isovaleric\u2003acid-DTHFPCIKFGPRSKGWVC(K(Palm))-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003222) Isovaleric\u2003acid-DTHFPCI(K(PEG3-Palm))FGPRSKGWVCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003223) Isovaleric\u2003acid-DTHFPCIKF(K(PEG3-Palm))PRSKGWVCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003224) Isovaleric\u2003acid-DTHFPCIKFGP(K(PEG3-Palm))SKGWVCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003225) Isovaleric\u2003acid-DTHFPCIKFGPRS(K(PEG3-Palm))GWVCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003226) Isovaleric\u2003acid-DTHFPCIKFGPRSKGWVC(K(PEG3-Palm))- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003176) Isovaleric\u2003acid-DTHFPCIKFGPRSKGWVC(K(PEG8))-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003241) Isovaleric\u2003acid-DTHFPCI(K(isoGlu-Palm))FEPRSKGCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003242) Isovaleric\u2003acid-DTHFPCIKF-K(isoGlu-Palm)-PRSKGCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003243) Isovaleric\u2003acid-DTHFPCIKFEP(K(isoGlu-Palm))SKGCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003265) Isovaleric\u2003acid-DTHFPCIKFEP(K(isoGlu-Palm))SKGWECK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003244) Isovaleric\u2003acid-DTHFPCIKFEPRS(K(isoGlu-Palm))GCK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003245) Isovaleric\u2003acid-DTHFPCIKFEPRSK(K(isoGlu-Palm))CK- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003246) Isovaleric\u2003acid-DTHFPCIKFEPRSKGCK(K(isoGlu-Palm))- NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003248) Isovaleric\u2003acid-DTHFPCI-K(Dapa-Palm)-FEPRSKGCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003249) Isovaleric\u2003acid-DTHFPCIK(F(Dapa-Palm))PRSKGCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003250) Isovaleric\u2003acid-DTHFPCIKFEP(K(Dapa-Palm))SKGCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003251) Isovaleric\u2003acid-DTHFPCIKFEPRS(K(Dapa-Palm))GCK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003252) Isovaleric\u2003acid-DTHFPCIKFEPRSK(K(Dapa-Palm))CK-NH 2 ;   (SEQ\u2003ID\u2003NO:\u2003253) Isovaleric\u2003acid-DTIFPCIKFEPRSKGC(K(Dapa-Palm))K- NH 2 ; or   (SEQ\u2003ID\u2003NO:\u2003254) Isovaleric\u2003acid-DTHFPCIKFEPRSKGC(K(Dapa-Palm))-NH 2 ,

Metadata:
- Claim Count in Document: 80.0
- Percentile: 99.0
- Lexical Diversity: 1.66667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14775469', '15828214', '16037982', '14800627', '15442229']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8827549017497516
- 35 USC 102 Novelty (BERT): 0.6940568029205311
- Combined Prediction Score: 0.8638850918668295
- Mean Citation Score: 708.0968359999997
- Max Citation Score: 889.48676
- Similarity Product: 741.6441090528847

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test